IL-33 and its decoy sST2 in patients with Alzheimer&apos;s disease and mild cognitive impairment by M. Saresella et al.
RESEARCH Open Access
IL-33 and its decoy sST2 in patients with
Alzheimer’s disease and mild cognitive
impairment
Marina Saresella1*†, Ivana Marventano1†, Federica Piancone1, Francesca La Rosa1, Daniela Galimberti2,4,5,
Chiara Fenoglio3,4,5, Elio Scarpini3,4,5 and Mario Clerici1,3
Abstract
Background: Interleukin-33 is a cytokine endowed with pro- and anti-inflammatory properties that plays a still
poorly defined role in the pathogenesis of a number of central nervous system (CNS) conditions including
Alzheimer’s disease (AD). We analyzed this cytokine and its decoy receptor sST2 in Alzheimer’s disease (AD) and
mild cognitive impairment (MCI).
Method: IL-33 and sST2 were analyzed in serum and CSF of AD and MCI patients, comparing the results to those
obtained in age-matched healthy controls (HC). Because of the ambiguous role of IL-33 in inflammation, the
concentration of both inflammatory (IL-1β and IL-6) and anti-inflammatory (IL-10) cytokines was analyzed as well in
serum and cerebrospinal fluid (CSF) of the same individuals. Finally, the effect of IL-33 on in vitro Aβ42-stimulated
monocytes of AD, MCI, and HC individuals was examined.
Results: As compared to HC, (1) IL-33 was significantly decreased in serum and CSF of AD and MCI, (2) sST2 was
increased in serum of AD and MCI but was undetectable in CSF, (3) serum and CSF IL-1β concentration was
significantly increased and that of IL-10 was reduced in AD and MCI, whereas no differences were observed in IL-6.
In vitro addition of IL-33 to LPS+Aβ 42-stimulated monocytes downregulated IL-1β generation in MCI and HC, but
not in AD, and stimulated IL-10 production in HC alone. IL-33 addition also resulted in a significant reduction of NF-
kB nuclear translocation in LPS+Aβ42-stimulated monocytes of HC alone.
Conclusions: These data support the hypothesis that IL-33 plays a complex anti-inflammatory role that is lost in
AD- and MCI-associated neuroinflammation; results herein also suggest a possible use of IL-33 as a novel
therapeutic approach in AD and MCI.
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Background
Interleukin-33 (IL-33) is a dual function cytokine pro-
duced by endothelial and epithelial cells as well as fibro-
blast, macrophages, adipocytes, smooth muscle, and
brain cells [1]. This cytokine is released as a full-length
active protein that can be inactivated by caspase-1,
caspase-3, and caspase-7-mediated cleavage [2, 3] or can
processed by different proteases into shorter forms char-
acterized by diverse biological activities [4–6]. The regu-
lation of IL-33 biological activity is complex as it is the
result of the interplay between the extra- and intracellu-
lar forms of this cytokine and its ability to bind two dif-
ferent isoforms of ST2, its cognate receptor. Binding of
extracellular IL-33 to ST2 on leukocytes, astrocytes, and
oligodendrocytes [7] mediates the biological effects of
this cytokine [8]. On the other hand, when expressed
intracellularly, IL-33 binds the p65 subunit of NF-kB [9];
the resulting IL-33/NF-kB p65 complex interferes with NF-
kB-dependent transcription by impeding p65-mediated
transactivation. This causes a negative modulation of NF-
kB activity, with a dampening effect on inflammation. An
additional actor that modulates the biological activity of IL-
33 is the soluble form of ST2 (sST2), a decoy receptor. As
is usually the case with decoy receptors, IL-33 binding to
sST2 limits its biological activity [10].
Th2 helper cells and mast cells express ST2 and re-
spond to IL-33, and type 2 innate lymphoid cells (ILC2)
are considered to be the signature IL-33-responsive cells
[11]. Thus, IL-33 targets ILC2 to produce IL-5 and IL-
13, resulting in the recruitment of eosinophils, the acti-
vation of DC, and Th2 differentiation [12–16]. A grow-
ing body of evidence suggests that IL-33 also controls
the accumulation and effector function of regulatory T
cell (Treg), either directly or indirectly via ILC2 activa-
tion and macrophage polarization [17–19]. Thus, IL-33
causes microglial and macrophage polarization to an
anti-inflammatory type-2 (M2) phenotype through the
IL-33/ST2 signaling pathway; this results in IL-10 gener-
ation and reduces IL-1β and IL-6 production [20–22].
IL-33 plays a yet poorly understood role in the patho-
genesis of Alzheimer’s disease (AD), a condition where
deposition of extracellular amyloid beta (Aβ) plaques in
the brain and neuronal cell death accompany neuro-
inflammation. In AD patients, the concentration of pro-
inflammatory cytokines, including interleukin IL-1β is
increased, possibly as a result of the activation of the
NLRP3 inflammasome, and immune regulatory mecha-
nisms, including those mediated by Tregs and PDL-1,
are impaired [23–27]. A more subtle form of neuroin-
flammation is also present in mild cognitive impairment
(MCI), a subjective and objective decline in cognitive
performance that is greater than expected for an individ-
ual’s age and education level, but does not meet criteria
for the diagnosis of AD [28]. Elderly MCI patients are at
high risk for developing AD; this situation thus repre-
sents a borderline condition between normal aging and
AD [29].
Correlates of MCI conversion to AD are still poorly
defined, even if neuroinflammation is strongly suspected
to play a role in this process [29–33]. Recent observa-
tions suggest a beneficial role of IL-33 in AD-associated
neuroinflammation. To summarize, (1) ex vivo results in
cellular models of AD indicated that over expression of
IL-33 decreases Aβ secretion and (2) autoptic data indi-
cate that IL-33 is significantly reduced in brains of AD
patients. Notably, in the APP/PS1 animal model of AD,
IL-33 administration was shown to restore the phagoly-
sosomal activity of the microglia, thus enhancing amyl-
oid β (Aβ) clearance, and to polarize monocytes to an
anti-inflammatory phenotype. This resulted in a signifi-
cant amelioration of AD symptoms [34], suggesting the
possibility that IL-33 is a neuroprotective cytokine in
AD [35]. This hypothesis nevertheless is not supported
by other results suggesting that IL-33 is present in high
concentrations in the neuropathological lesions of AD
brain and can exacerbate AD-associated neuroinflamma-
tion [36]. In the attempt to clarify the role of the ST2/
IL-33 axis in AD, we analyzed these proteins in AD,
MCI, and healthy controls (HC) individuals and ex-
plored the effect of IL-33 supplementation in an in vitro
system of Aβ-stimulated monocytes.
Materials and methods
Patients and controls
Ninety elderly Italian individuals were enrolled in the study
by the Neurology Department of the IRCCS Ca’ Granda
Ospedale Maggiore Policlinico, Italy. Thirty patients had a
diagnosis of AD, 30 patients had a diagnosis of mild cogni-
tive impairment (MCI), and 30 individuals were age and
sex matched healthy controls (HC). The clinical diagnosis
of AD was performed according to NINCDS-ADRDA work
group criteria [28] and further revisions [37], the clinical
diagnosis of MCI fulfilled Petersen’s operational criteria
[29]. Neuropsychological evaluation was performed with a
Mini-Mental State Examination (MMSE) [38] and Clinical
Dementia Rating Scale (CDR) [39].
All patients underwent a clinical interview, neuro-
logical and neuropsychological examination, routine
blood tests, brain MRI, and lumbar puncture (LP). The
mean age of AD patients (13 males and 17 females) was
74.3 years (age range 54–88 years) and that of MCI pa-
tients (8 males and 22 females) was 75.3 years (age range
63–84 years). All the AD patients were enrolled in a
Multidimensional Stimulation Rehabilitation program
designed for this pathology. Finally, the thirty age- and
sex-matched elderly subjects (HC) who were included in
the study were selected according to the SENIEUR
protocol for immuno-gerontological studies of European
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Community’s Control Action Programme on Aging [40];
their MMSE score was > 28.
The study was approved by the Ethics Committee of
Don Gnocchi Foundation and informed written consent
was obtained from all the included subjects before study
initiation.
Serum and CSF
Serum was collected in vacutainer tubes containing
serum separator (Becton Dickinson and Co., Rutherford,
NJ, USA) and were centrifuged at 3,000 rpm for 10min
to separate sera; CSF samples were collected by lumbar
puncture. Serum and CSF were used immediately or
stored at − 80 °C.
Blood sample collection and cell separation
Whole blood of a subset of individuals (5 AD, 5 MCI,
and 5 HC) was collected in vacutainer tubes containing
ethylenediaminetetraacetic acid (EDTA) (Becton Dickin-
son). Peripheral blood mononuclear cells (PBMC) were
separated on lympholyte separation medium (Cedarlane,
Hornby, Ontario, CA, USA) and washed twice in PBS at
1500 rpm for 10 min; viable leukocytes were determined
using a TC20 Automated Cell Counter (Biorad,
Hercules, CA, USA).
Cell cultures
PBMC (1 × 106/ml) were cultured in RPMI 1640 supple-
mented with 10% human serum, 2 mM L-glutamine, and
1% penicillin (Invitrogen Ltd, Paisley, UK) and incubated
at 37 °C in a humidified 5% CO2 atmosphere for 2 h in a
12-well plate for monocyte adhesion. After 2 h, non-
adhering PBMC were harvested and discarded and
monocytes grown on plate were either culture in
medium alone (unstimulated) or were or primed with
2 μg/ml lipopolysaccharide (LPS) for 2 h (Sigma-Al-
drich, St. Louis, MO, USA) before stimulation with
10 μg/ml of 1-42 amyloid-beta peptide (Aβ42) (Sigma-
Aldrich) in the absence/presence of 10 ng/ml of Human
Recombinant IL-33 (Biolegend, San Diego, CA, USA) for
24 h at 37 °C in a humidified 5% CO2 atmosphere. After
24 h, supernatants were collected and stored at − 20 °C;
adhering cells (monocytes) were collected and prepared
for FlowSight analysis.
Enzyme-linked immunosorbent assay (ELISA)
IL-33 (catalog number D3300B, sensitivity 1.51 pg/mL,
assay range 3.1–200 pg/ml, minimum detectable dose
(MDD) ranged from 0.069 to 1.51 pg/mL), sST2 (catalog
number DST200, sensitivity 13.5 pg/mL, assay range
31.3–2000 pg/mL, MDD ranged from 2.45 to 13.5 pg/
mL), IL-1β (catalog number DLB50, sensitivity 1 pg/mL,
assay range 3.9–250 pg/ml, MDD less than 1 pg/mL), IL-
6 (catalog number D6050, sensitivity 0.70 pg/mL, assay
range 3.1–300 pg/ml, MDD less than 0.70 pg/mL), and
IL-10 (catalog number D1000B, sensitivity 3.90 pg/mL,
assay range 7.8–500 pg/ml, MDD less than 3.90 pg/mL)
concentration was analyzed in serum and CSF by
commercially-available ELISA according to the manufac-
turer’s recommendations (Quantikine Immunoassay;
R&D Systems, Minneapolis, MN, USA, or Thermo
Fisher Scientific, Waltham, MA, USA). Serum and CSF
samples were not diluted prior to being utilized. A plate
reader (Sunrise, Tecan, Mannedorf, Switzerland) was
used and optical densities (OD) were determined at 450/
620 nm. All samples were performed in duplicates. The
same methods were used to measure IL-1β, IL-6, and
IL-10 in unstimulated and in LPS-primed and Aβ42-
stimulated PBMC supernatants in the presence/absence
of recombinant IL-33 (see above).
Western blot
A Qubit Protein Assay Kit was used for protein extrac-
tion; total protein amount was measured using a Qubit
3.0 Fluorometer (Thermo Fisher Scientific). Equal
amounts of protein (15 μg) from each sample, or 2 ng of
artificial truncated IL-33 (amino acids 112–270, 20 kDa)
(Recombinant Human IL33 carrier-free, Biolegend, San
Diego, CA, USA) used as positive control to confirm
that the bands correspond to IL-33 full length (amino
acids 1–270, 34–30 kDa), to the cleaved inactive forms
(amino acids 1–178, 22–20 kDa; amino acids 179–270,
13–12 kDa) [2, 3] or, finally, to the cleaved active forms
(amino acids 95–270, amino acids 99–270, and amino
acids 109–270; 19–15 kDa) [4], were separated by 10%
SDS-PAGE and transferred to PVDF membranes (Gen-
script). A pre-stained marker, broad range 11–190 KDa
(Cell signaling, Danvers, MA, USA), was also used,
PVDF membrane were treated by ONE-HOUR Western
detection kit (Genscript) and proteins were visualized
using a Chromosensor TMB substrate (Genscript). After
protein transfer, PVDF membranes were incubated with
a pretreatment solution for 5 min RT and then with the
WB solution and an α-human IL-33 Ab (Nessy-1)
(Abcam, Cambridge, UK) for 40 min. After three washes,
membranes were developed with a TMB substrate.
Cell culture and NFkB/7AAD intracellular staining
Monocytes that were either unstimulated or LPS-primed
and Aβ42-stimulated in the presence/absence of 10 ng/
ml of recombinant IL-33 were analyzed to evaluate nu-
clear translocation of NF-kB; the Amnis® NF-kB Trans-
location Kit was used according to the manufacturer’s
recommendations (Merck KGaA, Darmstadt, Germany).
Briefly, cells were fixed, permeabilized, and stained with
Anti-Hu NF-κB (p50) Alexa Fluor® 488 for 30 min RT.
After incubation, monocytes were washed and fixed and
10 μl of 7AAD were added.
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FlowSight analysis
The FlowSight (Amnis Corporation, Seattle, WA, USA)
is equipped with two lasers operating at 488 and 642
nm, two camera, and twelve standard detection chan-
nels. It simultaneously produces side scatter (darkfield)
images, one or two transmitted light (brightfield) images,
and up to ten channels of fluorescence imagery of every
cell. FlowSight acquires 2000 cells/s and operates with a
1-μm pixel size (× ~ 20 magnification) allowing
visualization of fluorescence from the membrane, cyto-
plasm, or nucleus. The IDEAS image analysis software
allows quantification of cellular morphology and fluores-
cence at different cellular localizations by defining
specific cellular regions (masks) and mathematical ex-
pressions that uses image pixel data or masks (feature)
by different wizards. Analysis of NF-kB translocation
was performed by Nuclear Localization Wizard using
the Similarity Feature. Briefly, nuclear translocation has
occurred if the NF-κB and nuclear fluorescence signals
overlap with similar shapes. The Bright Detail Similarity
is designed specifically to compare the small bright
image detail of two images and can be used to quantify
the co-localization of two probes (NF-kB and 7AAD) in
a defined region. The similarity score is the log trans-
formed Pearson’s correlation coefficient and it is a meas-
ure of the degree to which two images are linearly
correlated within a masked region and is calculated on a
double-positive region (NF-kB+7AAD+).
Statistical analysis
Quantitative data were not normally distributed (Shapiro-
Wilk test) and were summarized as median and interquar-
tile range (IQR) (25° and 75° percentile). Comparisons be-
tween groups were performed used a Kruskal-Wallis
ANOVA for each variable. Comparisons among the differ-
ent groups were made using a 2-tailed Mann-Whitney U
test performed for independent samples. Data analysis was
performed using the MedCalc statistical package (MedCalc
Software bvba, Mariakerke, Belgium).
Results
IL-33 isoforms
Analysis of the different isoforms of IL-33 (full-length;
cleaved inactive; cleaved active) was performed by West-
ern blotting in serum and CSF of AD, MCI and HC indi-
viduals. Results showed that the full-length IL-33 protein
(30–kDa band) was present in all analyzed serum and CSF
samples. Notably, in two cases an additional 20-kDa band,
corresponding to the cleaved (c), inactive form of IL-33
[3] was observed. These results are shown in Fig. 1.
IL-33 and sST2 serum and CSF concentration
IL-33 concentration was decreased in serum and CSF of
both AD and MCI individuals compared to HC (p value
vs. HC: serum, AD p = 0.02; MCI p = 0.04; CSF, AD p =
0.01; MCI p = 0.009). In contrast with these results,
Fig. 1 IL-33 isoforms. Interleukin-33 in serum (a–c) and CSF (d) samples of representative AD, MCI, and HC individuals. A 30-kDa band
corresponding to the full-length IL-33 protein was detected in all cases. An additional 20-kDa band was also present in two cases. Human
recombinant artificial truncated IL-33 (amino acids 112–270, 20 kDa) was used as a positive control (Ctrl); a pre-stained marker was also used.
Broad range 11–190 kDa
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serum concentration of the IL-33 decoy receptor sST2
was significantly increased in AD and MCI compared to
HC (p value vs. HC: p = 0.02 and p = 0.01, respectively)
(Fig. 2). CSF sST2 concentration was below the limit of
detection of the assay (33 pg/ml) in all the analyzed
samples (data not shown).
IL-1β, IL-6, and IL-10 serum and CSF concentration
IL-1β serum concentration was significantly increased in
AD and MCI sera compared to HC (p = 0.01 in both
cases), whereas that of IL-10 was significantly reduced in
both groups of patients compared to HC (p = 0.04 in
both cases). No significant differences were detected
when IL-6 serum concentration was compared between
the three groups. These results are shown in Fig 3.
In CSF, IL-1β concentration was significantly aug-
mented in AD and MCI compared to HC (p = 0.02 and
p = 0.01, respectively). IL-6 concentration was slightly
augmented and IL-10 concentration was marginally re-
duced in AD and MCI compared to what was seen in
HC but these differences did not reach statistical signifi-
cance (Fig. 3).
Recombinant IL-33 differentially modulates IL-1β, IL-6,
and IL-10 production by LPS-primed and Aβ42-stimulated
PBMC
Monocytes of AD, MCI, and HC individuals (n = 8 in all
cases) were LPS-primed and Aβ42-stimulated and IL-1β,
IL-6, and IL-10 production was measured by ELISA.
Whereas the production of these cytokines was minimal
(< 20 pg/ml in all cases) and comparable between the
three groups of individuals analyzed when monocytes
were unstimulated (medium alone) or when IL-33 was
added to the culture medium, LPS-primed, and Aβ42-
stimulated monocytes of AD and MCI patients produce
significantly augmented quantities of IL-1β (median, AD
= 230 ng/ml; MCI = 140 ng/ml ) compared to HC (me-
dian, 62 ng/ml; AD vs. HC p = 0.006; MCI vs. HC p =
0.03). Notably, IL-10 production by cells stimulated in
the same conditions was significantly reduced in AD
(median, 129 ng/ml) compared to HC individuals (median,
245 ng/ml) (p = 0.01).
Addition of IL-33 to cell cultures resulted in a signifi-
cant reduction of the production of both IL-1β (median,
36 pg/ml; p = 0.04) and IL-6 (median, 616 pg/ml; p =
0.01) in HC, and of IL-1β alone in MCI (median, 23 pg/
ml; p = 0.02). Finally, LPS+Aβ42-stimulated IL-10 pro-
duction was not modified by IL-33 in AD and MCI, but
was significantly increased in HC (median, 585 pg/ml;
p = 0.02) (Fig. 4).
These results support the idea that IL-33 reduces the
generation of proinflammatory cytokines and stimulates
that of anti-inflammatory cytokines, favoring the estab-
lishment of an anti-inflammatory milieu, and suggest
that IL-10-mediated anti-inflammatory mechanisms are
impaired/exhausted in AD and MCI.
Recombinant IL-33 reduces NF-kB nuclear translocation
Unstimulated as well as LPS-primed and Aβ42-stimu-
lated monocyte of AD (n = 5), MCI (n = 5), and HC
individuals (n = 5) were analyzed to verify the effect
of IL-33 on NF-kB nuclear translocation using the
FlowSight technology. No differences in NF-kB nu-
clear translocation were detected in unstimulated cells
(data not shown); upon antigenic stimulation, the IL-
33 was observed to significantly reduce NF-kB nuclear
translocation (p = 0.01) in HC alone (Fig. 5). These
results suggest that this is a pivotal IL-33 anti-
inflammatory mechanism that is possibly lost in MCI
and AD.
Discussion
Alzheimer’s disease is a highly prevalent form of demen-
tia characterized by the accumulation of extracellular
amyloid beta plaques in the brain, neuronal cell death,
Fig. 2 IL-33 and sST2. IL-33 and sST2 concentration in serum and CSF of AD, MCI, and age- and sex-matched HC individuals (N = 30 in each
group) was analyzed by ELISA in undiluted samples. The boxes stretch from the 25° to the 75° percentile; the line across the boxes indicates the
median values; the lines stretching from the boxes indicate extreme values. Statistical significance is shown
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and neuroinflammation. The pathogenesis of AD-
associated neuroinflammation includes an increased pro-
duction of proinflammatory cytokines, possibly driven by
the excessive activation of the inflammasome, a reduced
activity of Treg lymphocytes, and the dysregulation of
immune-mediated mechanisms of tolerance. Recent re-
sults suggest that IL-33 plays an important role as well
in the pathogenesis of AD. IL-33 is released by damaged
cell and can be produced by mast cells, macrophages,
and dendritic cells either as an active, full length, or as
an inactive differently cleaved form. Notably, although
only present in a small minority of samples, the cleaved,
biologically inert form of IL-33 was present in serum of
a subset of AD patients alone.
IL-33 is endowed with both pro- and anti-inflammatory
properties, hence the presence of contrasting data
Fig. 4 IL-1β, IL-6, and IL-10 production. IL-1β, IL-6, and IL-10 production by LPS-primed and Aβ42-stimulated monocytes of AD, MCI, and age- and
sex-matched HC individuals (N = 8 in each group) in the absence (straight lines) or presence (dotted lines) of human recombinant IL-33 (10 ng/
ml). The boxes stretch from the 25° to the 75° percentile; the line across the boxes indicates the median values
Fig. 3 IL-1β, IL-6, and IL-10 concentration. IL-1β, IL-6, and IL-10 concentration in serum (upper panels) and CSF (lower panels) of AD, MCI, and
age- and sex-matched HC individuals (N = 30 in each group). The boxes stretch from the 25° to the 75° percentile; the line across the boxes
indicates the median values; the lines stretching from the boxes indicate extreme values. Statistical significance is shown
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indicating both an increase and a reduction of IL-33 in
AD. We investigated the role of IL-33 in AD pathogenesis
both by directly measuring the concentration of this cyto-
kine and its decoy receptor in biological fluids of AD and
MCI patients and by analyzing the effect of IL-33 addition
in an in vitro model of Aβ42-stimulated monocytes of pa-
tients and healthy controls.
Results herein show that the IL-33/ST2 axis is deeply
impaired in MCI and AD. Thus, IL-33 concentration in
serum and CSF was significantly reduced, whereas the
concentration of sST2, the IL-33-specific decoy receptor,
was significantly increased in the same patients. In AD,
thus, lower amounts of IL-33 are produced and they
cannot optimally bind their cognate receptor on the sur-
face of cells, as they are trapped by soluble decoys.
That reduced concentrations of IL-33 are associated
with inflammation was indirectly confirmed by the ob-
servation that IL1β concentrations were significantly in-
creased whereas that of IL-10 was greatly reduced in the
same AD and MCI patients. The anti-inflammatory role
of IL-33 was further reinforced by the observation that
IL-33 supplementation resulted in the reduction of IL-
1β production by Aβ-stimulated cells of MCI and HC
and of IL-6 by cells of HC alone. Importantly, IL-33 in-
creased IL-10 production by cells of HC alone, suggest-
ing that the ability of monocytes of AD and MCI
individuals to secrete IL-10 in response to IL-33 is
deeply defective or exhausted.
IL-1β is augmented in AD. This cytokine promotes
amyloid plaque deposition, reduces phagocytic activity
by the microglia, stimulates the hyperphosphorylation of
τ protein, and affects synaptic plasticity. IL-10 produc-
tion, on the other hand, has repeatedly been shown to
be reduced in AD patients [24, 41, 42], in whom the IL-
10 gene SNPs associated with higher production of this
cytokine are also less frequently detected [33]. Results
herein could thus at least partially justify the genesis of
the proinflammatory mileu seen in AD and MCI as the
consequence of the reduced amounts of IL-33 seen in
these patients.
Notably, IL-33 significantly down-modulated NF-kB
nuclear translocation in cells of HC alone, indicating this
as possible mechanisms by which IL-33 favors the main-
tenance of an anti-inflammatory milieu in individuals in
Fig. 5 NF-kB nuclear translocation. a Representative images of NF-kB nuclear translocation in unstimulated (MED) and in LPS-primed and Aβ42
stimulated monocytes. First column = cells in brightfield (BF); second column = NF-kB-FITC fluorescence; third column = 7AAD fluorescence;
fourth column = NF-kB and 7AAD merged fluorescence. Fourth column: the upper image showing the red nuclear image (7AAD staining)
surrounded by the green cytoplasmic NF-kB staining indicates lack of nuclear translocation (similarity score = − 1.85); the lower image, where NF-
kB and the nuclear dye are colocalized, indicates nuclear translocation (similarity score = + 2.3). b NF-κB/7-AAD similarity histograms indicating
the percentage of cells in which NF-kB is untranslocated (negative similarity score) or translocated (positive similarity score) to the nucleus. c–e
NF-kB nuclear translocation in unstimulated (MED) and in LPS-primed and Aβ42 stimulated monocytes in the absence or in the presence of
human recombinant IL-33 (10 ng/ml); data obtained with cells of representative AD (c), MCI (d), and HC (e) individuals are shown. Summary
results are presented in the bar graphs. The boxes stretch from the 25° to the 75° percentile; the line across the boxes indicates the median
values. Statistical significance is shown
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whom dementia is not present. Thus, IL-33 was shown
to have a regulatory effect on the NF-kB pathway, which
is mediated by its ability to binding the NF-kB p65 sub-
unit [9]. The IL-33/NF-kB p65 complex impedes p65-
mediated transactivation; this downregulates NF-kB ac-
tivity, with a dampening effect on inflammation. The ob-
servation that this effect was lost in cells of MCI and AD
individuals suggests that the role of IL-33 in the patho-
genesis of AD- and MCI-associated inflammation is
multifaceted, as this cytokine would exert its effect both
at the intracellular and at the extracellular level. To
summarize, (1) reduction of IL-33 production per se, (2)
increased concentrations of the sST2 decoy receptor,
and (3) an impairment of the ability of IL-33 to induce
NF-kB nuclear translocation are different mechanism
that can explain the proinflammatory role played by IL-
33 in AD and MCI.
IL-33 was also reported to induce the polarization of
monocytes toward an M2 anti-inflammatory phenotype;
these monocytes produce IL-10, whose concentration, as
indicated above, is greatly reduced in AD and MCI indi-
viduals [43, 44]. M2 polarization by IL-33 is possibly ex-
plained by the observation that the IL-33 binding to ST2
negatively regulates TLR signaling by competing with
MyD88 [45, 46]. The IL-33/ST2 complex thus sup-
presses IL-1β generation and the down-stream activation
of the TLR signaling pathway by sequestration of
MyD88 with the consequence of further inhibiting NF-
kB and activating MAP kinases [46]. IL-33 indeed acti-
vates ERK1\2 and STAT3, facilitating binding of STAT3
to the − 1954 to − 1936 bp sequence upstream of the IL-
10 transcription start site, thereby promoting its tran-
scription in macrophages [47]. Although we did not
analyze M1 and M2 monocytes in this study, previously
published data indicate that M2 cells are significantly re-
duced in AD. The reduction of M2 monocytes seen in
AD could explain why IL-33 supplementation did not
increase IL-10 production by monocytes of AD and MCI
individuals in our in vitro system and could be a third
way to justify why the lower quantities of IL-33 seen in
AD results in inflammation in these patients.
IL-33 has repeatedly been suspected to be involved in
the pathogenesis of CNS diseases. In particular, the ad-
ministration of recombinant IL-33 was shown to pro-
mote recovery in a mouse model of autoimmune
encephalomyelitis (EAE) [48, 49] and to provide neuro-
protection in a mouse model of contusion spinal cord
injury (SCI) [43]. In the APP/PS1 animal model of AD,
IL-33 attenuated AD pathology and memory deficit and
stimulated the polarization of microglia in an anti-
inflammatory direction [34, 50]. Finally, recent data
obtained in a small groups of MCI who did or did not
convert to AD over time [31] showed that higher
amounts of IL-33-producing CD14+ monocytes were
seen in AD-non converters, in whom percentages of
CD14+/IL-33+ cells positively correlated with the vol-
umes of both left and right hippocampus.
Finally, recent data obtained in a small groups of MCI
who did or did not convert to AD over time [31] showed
that higher amounts of IL-33-producing CD14+ mono-
cytes were seen in AD-non converters, in whom per-
centages of CD14+/IL-33+ cells positively correlated
with the volumes of both left and right hippocampus. In
the attempt to further analyze possible correlations be-
tween hippocampus volumes and IL-33, we are planning
to verify the immunological effects of IL-33 on human
microglia cell lines.
Conclusions
IL-33 was shown to have a neuroprotective role in AD
secondary to the reduction of Aβ secretion and the activa-
tion of Aβ phagocytosis by the microglia [35]. Findings
herein offer an immune explanation as well to the protect-
ive role of IL-33 in AD; these results warrant the investiga-
tion of this cytokine in treatment and rehabilitation
programs for AD.
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